Effects of dialyzable transfer factor in patients with breast cancer Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Genetic Therapy
  • HLA-A2 Antigen
  • Immunologic Factors
  • Immunotherapy, Active
  • Interleukin-2
  • Melanoma
  • Recombinant Fusion Proteins
  • Tumor Cells, Cultured

abstract

  • Five patients with advanced breast cancer were treated with pooled dialyzable transfer factor from healthy adult donors. The period of treatment ranged from 21 to 310 days, the total dose from 20 to 257 ml. Transfer factor did not elicit inflammatory or hypersensitivity reactions or detectable formation of antibody to itself, nor any hematological or biochemical abnormalities or other side effects. Three patients became responsive (by skin test) to tuberculin and/or streptococcal antigens. Marked partial regression of the breast cancer, lasting 6 months, was observed in one patient.

publication date

  • December 1974

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1073/pnas.71.6.2319

PubMed ID

  • 4366760

Additional Document Info

start page

  • 2319

end page

  • 23

volume

  • 71

number

  • 6